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Abbreviation: m, male; f, female; TNMG, tumor size, node involvement, metastasis, grade 'Neubauer improved' hemocytometer. Median viability after thawing was 92%. Cells were rested in serum-free medium (CTL Test medium; Cellular Technology Ltd) for at least 2 h at 37°C, 5% CO 2 at a cell concentration of 2×10 6 /ml in 50 ml polypropylene tubes with no more than 5 ml per tube. The cap was slightly loosened for gas exchange. Median cell recovery after resting was 83.1%.
For the ELISPOT the IFN-γ-ELISPOT PRO kit (Mabtech, Nacka, Sweden) with precoated plates (monoclonal antibody 1-D1K), the monoclonal detection antibody 7-B-6-1-ALP conjugated and BCIP/NBTplus substrate solution was used. Blocking of the plates was done with CTL Test medium. PBMC were seeded in quadruplicates at 1.5×10 5 cells per well and directly stimulated with selected peptides (each peptide, 5 μg/ml) in serum-free CTL Test medium, supplemented with CD28 (1 μg/ml; BD Biosciences, San Jose, CA) and recombinant IL-2 (Proleukin, 2U/ml; Chiron, Emeryville, CA) for 24 h. The peptides were selected from sequences of TAAs shown to be overexpressed in metastatic RCC lesions and/or the vaccine cells, using HLA-A*02:01 motif-based epitope predictions available on the web (http://www.syfpeithi.de), or as published in the literature. Several peptides were identified by elution from the RCC-26 cell line (Stefan Stevanovic, Tübingen) and tested for their expression on the vaccine cell line. Peptides specific for the following antigens were used as described in Buchner et al., (3) for survivin, Cyclin D1, adipophilin, C-Met proto-oncogen, regulator of G protein signaling (RGS5), vascular endothelial growth factor (VEGF), NY-ESO-1, and additionally: carbonic anhydrase IX (CA IX, G250) (GLLFAVTSV; HLSTAFARV 217-225 , (4), matrix metalloproteinase 7 (MMP7) (CLLPGSLAL, FLYAATHEL), preferentially expressed antigen in melanoma (PRAME) (VLDGLDVLL 100 tein (SMPDFDLHL), B-cell translocation gene 1 protein (BTG1) (TLWVDPYEV 103-111 ), p53-induced gene 10 protein (PIG10) (YLPELLQTV 228-236 ), leukocyte receptor cluster (LRC) member 4, also known as malignant cell expression-enhanced gene/tumor progression-enhanced or membrane-bound O-acyltransferase domain-containing protein 7 (LENG4) (GLLPDVPSL [141] [142] [143] [144] [145] [146] [147] [148] [149] ). The HLA-A2 CEF peptide pool (PANATecs, Tübingen, Germany) was used as positive control. Culture medium without peptide was used as negative control.
Spots were counted with AID reader system ELR03 with software version 4.0 and 5.0 (Autoimmun Diagnostika [AID], Strassberg, Germany) and controlled by human audit. Spot parameters were established using the positive and negative control wells. Artifacts and faint small background spots observed in the negative control wells were excluded (see representative example, Supplementary Figure S7 ).
Responses were not considered positive, if spot number was equal or below 10 spots over background per 1.5×10 6 cells. Responses were considered to be positive, if the mean spot number of quadruplicates for a given peptide were at least two-fold over the mean background spot number. A response was considered to be vaccine induced, if the ratio of peptide mean to background mean for a given vaccination time point was at least two-fold over the corresponding prevaccination ratio.
The performance of ELISPOT assays was externally validated by participation in the immune assay proficiency panels of the international Cancer Immunotherapy Consortium (1) and the CIMT Association for Immunotherapy of Cancer (2). While our laboratory has not established GLP conditions, this study was performed using standard operating procedures (SOPs) covering the processing, freezing, storage, and thawing of cells and the ELISPOT assay. All conditions and reagents were standardized and pretested. The operator was the same throughout the clinical study.
Flow Cytometry
For surface immunostaining the following directly labelled monoclonal antibodies were purchased from BD Biosciences: CD3 (clone UCHT1, FITC and Horizon V500), CD4 (clone SK3, PE-Cy7 and PerCP-Cy5.5), CD8 (clone RPA-T8, Alexa Fluor 700), CD25 (clone M-A251, PerCP-Cy5.5), CD39 (clone TÜ66, APC), CD127 (clone hIL-7R-M21, PE), CD11b (clone ICRF44, Pacific blue), CD15 (clone HI98, FITC), CD14 (clone IV M_P9, APC-H7), CD33 (clone P67.6, PerCP-Cy5.5), CD124 (IL-4Rα, clone 25463, PE), HLA-DR (clone G46-6, APC); CD3 and CD19 (clone SK7 and clone SJ25C1, respectively, PE-Cy7, for dump channel in the MDSC analysis). For Treg analysis the monoclonal antibody FoxP3 (clone PCH101, eFluor450; eBiosciences, Frankfurt, Germany) was used. , for MDSC analysis 1.55×10 6 . The PMT voltage was adjusted using un-
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Supplementary stained cells for all parameters. The gating strategy for Treg analysis is shown in Supplementary Figure S4 and for MDSC analysis in Supplementary Figure S5 .
Cytokine/Chemokine Assays
Commercially available ELISA kits and protocols (R&D Systems GmbH, Wiesbaden, Germany) were used for VEGF, VEGF-C, VEGF-D, TGFβ1, and PGE 2 . For all other cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17, TNFα, IFNγ, GM-CSF, G-CSF) and chemokines CXCL8 (IL-8), CXCL9 (MIG), CXCL10 (IP-10), CCL2 (MCP-1), CCL4 (MIP-1β), and CCL5 (RANTES) the Luminex (BioPlex, BioRad, Munich, Germany) and the multiplex cytokine bead array systems from BD Biosciences (CBA kit for chemokines and CBA Flex Set) were applied and performed according to the manufacturer's instructions.
Blood for serum samples were taken before and after first vaccination, and before and after 4th, 5th, 8th, 9th, 10th vaccinations at the time points when the dosage was enhanced and the skin biopsies were taken (Supplementary Figure S1 ). All blood samples were directly processed for serum preparation after 30-min incubation and stored immediately. PBMC (5x10 5 ) from the time 
Analysis of the Demethylation of the Foxp3 Gene
Genomic DNA was isolated using the DNeasy blood and tissue kit (Qiagen, Hilden, Germany). Bisulphite treatment of genomic DNA was performed as described (7) with minor modifications. A quantitative real-time (qRT) PCR-based methylation assay with methylation-and demethylation-specific amplification primers was used to analyze the Foxp3 Treg-specific demethylated region (TSDR) DNA as described (8). Each sample was analyzed in triplicate using a LightCycler 480 System (Roche, Mannheim, Germany). Cycling condi- tions consisted of a 95°C preheating step for 10 min and 50 cycles of 95°C for 15 s followed by 1 min at 61°C. Titrated PCR products were generated using DNA from sorted naive and regulatory T cells for a standard curve. Amounts of methylated and unmethylated Foxp3 DNA were estimated from calibration curves by linear regression on crossing points from the second-derivative maximum method. The proportion of unmethylated DNA was computed as the ratio of unmethylated Foxp3 TSDR-DNA and the sum of methylated and unmethylated Foxp3 TSDR-DNA. For female patients, this ratio was corrected with a factor of 2 due to the fact that one of the two TSDR alleles is methylated as a result of chromosome X inactivation.
Microarray Analysis
Tissue samples from 32 patients with clear-cell RCC metastases were collected, snap-frozen, and stored in liquid nitrogen after written informed consent had been obtained. The study was approved by the Ethics Committee of the Ludwig-Maximilians-University, Munich, Germany. Cryostat sections were made and laser microdissection was used to isolate tumor cells (PALM MicroBeam, Zeiss, Munich, Germany). Total RNA was extracted from these cells and also from RCC-26 and the vaccine cells (RNeasy Micro kit; Qiagen, Hilden, Germany). RNA integrity was tested by capillary electrophoresis (2100 Bioanalyzer; Agilent, Santa Clara, CA). RNA amplification and hybridization
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Supplementary Figure S4 . Gating strategy to determine the frequencies of CD4 on oligonucleotide microarrays (GeneChip Human Genome U133 Plus 2.0 array, Affymetrix, Santa Clara, CA) were performed according to the manufacturer's instruction. Normalized expression values were calculated for every transcript, using dChip software (9). 
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